Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials.
Ostrowitzki S, Bittner T, Sink KM, Mackey H, Rabe C, Honig LS, Cassetta E, Woodward M, Boada M, van Dyck CH, Grimmer T, Selkoe DJ, Schneider A, Blondeau K, Hu N, Quartino A, Clayton D, Dolton M, Dang Y, Ostaszewski B, Sanabria-Bohórquez SM, Rabbia M, Toth B, Eichenlaub U, Smith J, Honigberg LA, Doody RS. Ostrowitzki S, et al. Among authors: blondeau k. JAMA Neurol. 2022 Nov 1;79(11):1113-1121. doi: 10.1001/jamaneurol.2022.2909. JAMA Neurol. 2022. PMID: 36121669 Free PMC article. Clinical Trial.
Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer's Disease Treated with Escalating Doses for up to 133 Weeks.
Guthrie H, Honig LS, Lin H, Sink KM, Blondeau K, Quartino A, Dolton M, Carrasco-Triguero M, Lian Q, Bittner T, Clayton D, Smith J, Ostrowitzki S. Guthrie H, et al. Among authors: blondeau k. J Alzheimers Dis. 2020;76(3):967-979. doi: 10.3233/JAD-200134. J Alzheimers Dis. 2020. PMID: 32568196 Free PMC article. Clinical Trial.
Safety, Tolerability, and Pharmacokinetics of High-Volume Subcutaneous Crenezumab, With and Without Recombinant Human Hyaluronidase in Healthy Volunteers.
Dolton MJ, Chesterman A, Moein A, Sink KM, Waitz A, Blondeau K, Kerchner GA, Hu N, Brooks L, Wetzel-Smith MK, Roden A, Deshmukh A, Peng K, Carrasco-Triguero M, Smith J, Ostrowitzki S, Quartino A. Dolton MJ, et al. Among authors: blondeau k. Clin Pharmacol Ther. 2021 Nov;110(5):1337-1348. doi: 10.1002/cpt.2385. Epub 2021 Aug 27. Clin Pharmacol Ther. 2021. PMID: 34347883 Clinical Trial.
Randomized clinical trial: effect of the 5-HT4 receptor agonist revexepride on reflux parameters in patients with persistent reflux symptoms despite PPI treatment.
Tack J, Zerbib F, Blondeau K, des Varannes SB, Piessevaux H, Borovicka J, Mion F, Fox M, Bredenoord AJ, Louis H, Dedrie S, Hoppenbrouwers M, Meulemans A, Rykx A, Thielemans L, Ruth M. Tack J, et al. Among authors: blondeau k. Neurogastroenterol Motil. 2015 Feb;27(2):258-68. doi: 10.1111/nmo.12484. Epub 2014 Dec 21. Neurogastroenterol Motil. 2015. PMID: 25530111 Free PMC article. Clinical Trial.
Weakly acidic reflux.
Tack J, Blondeau K. Tack J, et al. Among authors: blondeau k. Dig Dis. 2009;27(1):58-61. doi: 10.1159/000210105. Epub 2009 May 8. Dig Dis. 2009. PMID: 19439962 Review.
Reflux cough.
Blondeau K, Sifrim D, Dupont L, Tack J. Blondeau K, et al. Curr Gastroenterol Rep. 2008 Jun;10(3):235-9. doi: 10.1007/s11894-008-0049-0. Curr Gastroenterol Rep. 2008. PMID: 18625132 Review.
Nocturnal gastroesophageal reflux revisited by impedance-pH monitoring.
Fornari F, Blondeau K, Mertens V, Tack J, Sifrim D. Fornari F, et al. Among authors: blondeau k. J Neurogastroenterol Motil. 2011 Apr;17(2):148-57. doi: 10.5056/jnm.2011.17.2.148. Epub 2011 Apr 27. J Neurogastroenterol Motil. 2011. PMID: 21602991 Free PMC article.
85 results